CORCEPT THERAPEUTICS INC (CORT)
US2183521028 - Common Stock
We assign a fundamental rating of 7 out of 10 to CORT. CORT was compared to 194 industry peers in the Pharmaceuticals industry. CORT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CORT is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make CORT suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
In the past year CORT had a positive cash flow from operations.
Each year in the past 5 years CORT has been profitable.
In the past 5 years CORT always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 18.08%, CORT belongs to the top of the industry, outperforming 97.92% of the companies in the same industry.
Looking at the Return On Equity, with a value of 22.20%, CORT belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
CORT has a Return On Invested Capital of 18.79%. This is amongst the best in the industry. CORT outperforms 94.79% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly below the industry average of 42.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.08% | ||
| ROE | 22.2% | ||
| ROIC | 18.79% |
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
1.3 Margins
The Profit Margin of CORT (22.56%) is better than 95.31% of its industry peers.
CORT's Profit Margin has declined in the last couple of years.
CORT has a better Operating Margin (22.81%) than 89.06% of its industry peers.
In the last couple of years the Operating Margin of CORT has declined.
Looking at the Gross Margin, with a value of 98.44%, CORT belongs to the top of the industry, outperforming 98.96% of the companies in the same industry.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.81% | ||
| PM (TTM) | 22.56% | ||
| GM | 98.44% |
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
2. Health
2.1 Basic Checks
CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CORT has less shares outstanding than it did 1 year ago.
CORT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 27.02 indicates that CORT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 27.02, CORT belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 27.02 |
ROIC/WACC2.08
WACC9.05%
2.3 Liquidity
CORT has a Current Ratio of 3.70. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CORT (3.70) is comparable to the rest of the industry.
A Quick Ratio of 3.64 indicates that CORT has no problem at all paying its short term obligations.
The Quick ratio of CORT (3.64) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
CORT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.56%, which is quite impressive.
Measured over the past 5 years, CORT shows a small growth in Earnings Per Share. The EPS has been growing by 6.00% on average per year.
Looking at the last year, CORT shows a very strong growth in Revenue. The Revenue has grown by 39.65%.
Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 13.94% on average per year.
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y6%
EPS Q2Q%46.43%
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Sales Q2Q%47.69%
3.2 Future
Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 26.44% on average per year.
CORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.69% yearly.
EPS Next Y46.02%
EPS Next 2Y37.07%
EPS Next 3Y59.58%
EPS Next 5Y26.44%
Revenue Next Year45.26%
Revenue Next 2Y30.42%
Revenue Next 3Y32.89%
Revenue Next 5Y16.69%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 44.38, which means the current valuation is very expensive for CORT.
Based on the Price/Earnings ratio, CORT is valued a bit cheaper than the industry average as 79.69% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.96. CORT is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 31.33, CORT can be considered very expensive at the moment.
75.52% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, CORT is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.38 | ||
| Fwd PE | 31.33 |
4.2 Price Multiples
CORT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CORT is cheaper than 77.60% of the companies in the same industry.
80.21% of the companies in the same industry are more expensive than CORT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.11 | ||
| EV/EBITDA | 36.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CORT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 59.58% in the coming years.
PEG (NY)0.96
PEG (5Y)7.4
EPS Next 2Y37.07%
EPS Next 3Y59.58%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (11/21/2024, 8:20:39 PM)
After market: 56.01 +0.09 (+0.16%)55.92
-0.17 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.86B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.38 | ||
| Fwd PE | 31.33 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.96
PEG (5Y)7.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.08% | ||
| ROE | 22.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 22.81% | ||
| PM (TTM) | 22.56% | ||
| GM | 98.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y
EPS Q2Q%
EPS Next Y46.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y